How Analysts Rated Allergan plc (NYSE:AGN) Last Week?

Rodiano Bonacci
Декабря 7, 2017

Therefore 65% are positive.

Allergan PLC. has a 52 week low of $160.07 and a 52 week high of $256.80. $269.86's average target is 63.43% above currents $165.12 stock price. Allergan Inc. had 96 analyst reports since July 29, 2015 according to SRatingsIntel. J P Morgan Chase & Co set a $275.00 price target on Allergan and gave the stock a "buy" rating in a research report on Sunday, October 22nd.

ILLEGAL ACTIVITY WARNING: "Allergan (AGN) PT Set at $191.00 by Cantor Fitzgerald" was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. The firm has "Neutral" rating by Mizuho given on Thursday, October 19. JMP Securities upgraded the shares of CACC in report on Wednesday, August 26 to "Market Perform" rating. Wells Fargo & Company reissued an outperform rating and set a $245.00 target price (down previously from $258.00) on shares of Allergan in a research report on Thursday, November 2nd. The rating was maintained by Mizuho on Friday, November 13 with "Buy".

Allergan announced that its Board of Directors has authorized a share repurchase plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. The firm has "Buy" rating by RBC Capital Markets given on Thursday, August 3. The company has market cap of $22.10 million. It now has negative earnings. After $-0.07 actual earnings per share reported by National Oilwell Varco, Inc. for the previous quarter, Wall Street now forecasts -42.86% EPS growth.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The firm has a market cap of $55,508.12, a PE ratio of 10.82, a price-to-earnings-growth ratio of 1.12 and a beta of 1.11. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ's disease.

Looking into last 5 trades, the stock observed a return of nearly -3.18%. When it comes to net revenue, the average estimate from a total of 18 analysts is 4.27 billion - compared to $3.86 billion posted in the year-ago period. AGN's total short interest was 7.84 million shares in December as published by FINRA. It has underperformed by 20.12% the S&P500. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.20 as current ratio and on the opponent side the debt to equity ratio was 0.46 and long-term debt to equity ratio also remained 0.40. Today it is now trading at $168.00 (2.26%), with an average volume 3845.95, its volume today is 3,660,241. Analysts expect Allergan plc to earn $17.98 per share next year, which means the company should continue to be able to cover its $2.80 annual dividend with an expected future payout ratio of 15.6%.

The Piotroski score is a discrete score ranging from 0-9 that shows nine criteria used to find out the strength of a company's financial position. Morgan Stanley raised shares of Allergan from an equal weight rating to an overweight rating and boosted their price target for the company from $171.92 to $200.00 in a research report on Wednesday, November 29th. Cubic Asset Mngmt Llc invested in 2,311 shares. Gemmer Asset Management Limited Liability Company invested 0.01% of its portfolio in Allergan plc (NYSE:AGN). Grassi Invest Mgmt holds 0.36% in Allergan plc (NYSE:AGN) or 8,395 shares. Toth Fincl Advisory Corp reported 958 shares.

Let's take an assessment at how Allergan plc (AGN) has been performing.

Several other institutional investors have also sold shares of the company. Dowling & Yahnke Ltd Liability Corporation holds 0.05% or 2,097 shares in its portfolio.

Currently, 0.10% of Allergan plc (NYSE:AGN) are owned by insiders with 85.07% six-month change in the insider ownership. Moreover, Frontier Investment has 0.71% invested in Allergan plc (NYSE:AGN).

In related news, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. About 1.70 million shares traded. (NYSE:NOV) has risen 11.97% since December 6, 2016 and is uptrending. It has underperformed by 3.46% the S&P500.

A good method of evaluating a public company's profitability is by taking a look at its Earnings per Share (EPS) performance. The New York-based Blackrock Inc. has invested 0% in the stock. (NYSE:TJX). Shelton Capital Mgmt, California-based fund reported 6,916 shares.

Analysts await Capricor Therapeutics, Inc. First Financial Bank Of Omaha reported 21,648 shares. NY now owns 906 shares of the company's stock valued at $220,000 after buying an additional 6 shares during the last quarter.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Altre relazioni

Discuti questo articolo

Segui i nostri GIORNALE

ULTIME NOTIZIE

ALTRE NOTIZIE